The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Open accessAbstract
Most normal mammalian cells have a finite lifespan, thought to constitute a protective mechanism against unlimited proliferation. This phenomenon, called senescence, is driven by telomere attrition, which triggers the induction of tumour suppressors including p16(INK4a) (ref. 5). In cultured cells, senescence can be elicited prematurely by oncogenes; however, whether such oncogene-induced senescence represents a physiological process has long been debated. Human naevi (moles) are benign tumours of melanocytes that frequently harbour oncogenic mutations (predominantly V600E, where valine is substituted for glutamic acid) in BRAF, a protein kinase and downstream effector of Ras. Nonetheless, naevi typically remain in a growth-arrested state for decades and only rarely progress into malignancy (melanoma). This raises the question of whether naevi undergo BRAF(V600E)-induced senescence. Here we show that sustained BRAF(V600E) expression in human melanocytes induces cell cycle arrest, which is accompanied by the induction of both p16(INK4a) and senescence-associated acidic beta-galactosidase (SA-beta-Gal) activity, a commonly used senescence marker. Validating these results in vivo, congenital naevi are invariably positive for SA-beta-Gal, demonstrating the presence of this classical senescence-associated marker in a largely growth-arrested, neoplastic human lesion. In growth-arrested melanocytes, both in vitro and in situ, we observed a marked mosaic induction of p16(INK4a), suggesting that factors other than p16(INK4a) contribute to protection against BRAF(V600E)-driven proliferation. Naevi do not appear to suffer from telomere attrition, arguing in favour of an active oncogene-driven senescence process, rather than a loss of replicative potential. Thus, both in vitro and in vivo, BRAF(V600E)-expressing melanocytes display classical hallmarks of senescence, suggesting that oncogene-induced senescence represents a genuine protective physiological process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mouse models of melanoma and human nevi (both oncogene driven) show accumulation of SA-β-gal+–CDKN2A+ foci224,225.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [225]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hallmarks of senescent cells were subsequently identified in dermal premalignant lesions, specifically human melanocytic naevi 81,82 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [81]
In the citing paper
“Oncogene-induced senescence protects against tumor initiation 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“OIS is a powerful tumor suppressor mechanism 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [35]
In the citing paper
“in vitro experiments showed that cells that lack functional p53 or overexpress the H3K9me3 demethylase JMJD2c46,50 — which therefore cannot enter senescence in response to pro-senescent oncogenes such as Ras-G12V or Braf-V600E46,51 — also failed to enter VIS and lacked a SASP upon infection with SARS-CoV-2 (ref.28).”
From COVID-19 and cellular senescence (2023) · cites this paper as [51]
In the citing paper
“Studies have demonstrated high levels of senescence in premalignant lesions and lower levels in invasive disease, suggesting a role for senescence in blocking malignant progression [2,31,32].”
From Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies (2020) · cites this paper as [32]
In the citing paper
“human melanocytic naevi (an OIS model), remain non-proliferative for decades without transformation into malignant melanoma 25”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“This is a seminal study that identified OIS of human melanocytic naevi.”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [25]
In the citing paper
“Senescence markers are detected in premalignant tumor lesions but not at later stages of tumor development [17,18,19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Benign melanocytic lesions, which are melanoma precursors in humans, express high p16 and are an in vivo example of OIS [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, such telomeres are not visibly shorter than functional telomeres [114] in human melanocytic nevi with frequent BRAF mutations, a typical OIS feature in vivo [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Indeed, its locus is more commonly deleted or silenced than mutated in melanoma, the more malignant later stage of disease [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“For example, N-RAS- or B-RAF-activating mutations are commonly found in benign melanocytic nevi that show features of senescence, such as elevated p16 levels, but that do not express appreciable levels of ARF or p53 [19,55].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“In humans, Ras activation appears to induce only p16 [19,127].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“senescence occurs during the formation of benign cutaneous melanocytic nevi that express an oncogenic form of BRAF [19].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [19]
In the citing paper
“Importantly, this work also provided evidence for the occurrence of 4N senescent cells in human melanocyte naevi, the first in vivo senescence model, 94 suggesting that the G2 exit program has a more general role in senescence.”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [94]
In the citing paper
“The acronym oncogene-induced senescence (OIS) was coined following the demonstration that the aberrant activation of oncogenes (e.g., Ras, BRAF V600E, and c-Myc) or loss of tumor suppressor genes (e.g., PTEN) temporarily arrests a large variety of tumors in a pre-malignant state 180-183 (Figure 3B).”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [182]
In the citing paper
“BRAFV600E mutation alone is often insufficient to drive malignant transformation of melanocytes24.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [24]
In the citing paper
“For example, developmental senescent cells express p21WAF1/Cip1 but not p16INK4a9,10, while the reverse is observed in melanocytic nevi36,37.”
From Algorithmic assessment of cellular senescence in experimental and clinical specimens (2021) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Lowe, S. W., Cepero, E., & Evan, G. I. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,374
Research works printed but not linked: 1
- Peeper, D. S. & Mooi, W. J. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41, S139–S143 (2002)
Cited by
Sorted by citations
Items 901–1,000 of 1,009
Pathways from senescence to melanoma: focus on MITF sumoylation
Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Oncogene · doi:10.1038/onc.2017.292 · Cited by 43
Riefolo, M., Porcellini, E., Dika, E., Broseghini, E., & Ferracin, M. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12412 · Cited by 43
Liu, H., Osterburg, A. R., Flury, J. L., Swank, Z., McGraw, D. W., Gupta, N., Wikenheiser‐Brokamp, K. A., Kumar, A. R., Tazi, A., Inoue, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132048 · Cited by 43
Zhang, P., Furukawa, K., Opresko, P. L., Xu, X. Z. S., Bohr, V. A., & Mattson, M. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03779.x · Cited by 43
Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis
Dean, J. P., & Nelson, P. S. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604087 · Cited by 43
A quantitative model for age-dependent expression of the p16INK4a tumor suppressor
Tsygankov, D., Liu, Y., Sanoff, H. K., Sharpless, N. E., & Elston, T. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904405106 · Cited by 43
Insights into melanoma: targeting the mTOR pathway for therapeutics
Pópulo, H., Soares, P., & Lopes, J. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691472 · Cited by 43
Lipid Phosphate Phosphatase-2 Activity Regulates S-phase Entry of the Cell Cycle in Rat2 Fibroblasts
Morris, K., Schang, L. M., & Brindley, D. N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511710200 · Cited by 43
A High-Throughput Method to Identify Novel Senescence-Inducing Compounds
Ewald, J. A., Peters, N. R., Desotelle, J. A., Hoffmann, F. M., & Jarrard, D. F. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109340314 · Cited by 43
Graf, M., Hartmann, N., Reichwald, K., & Englert, C. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.02.012 · Cited by 42
Amemiya, Y., Yang, W., Benatar, T., Nofech‐Mozes, S., Yee, A., Kahn, H. K., Holloway, C. M. B., & Seth, A. K. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0921-0 · Cited by 42
Programmed cell senescence: role of IL-6 in the pituitary
Sapochnik, M., Fuertes, M., & ARZT, E. S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0026 · Cited by 42
Aging tumour cells to cure cancer: “pro-senescence” therapy for cancer
Calcinotto, A., & Alimonti, A. (2017) · Swiss Medical Weekly · doi:10.57187/smw.2017.14367 · Cited by 42
Kim, Y. H., & Park, T. J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.295 · Cited by 42
Ha, L., Ponnamperuma, R. M., Jay, S., Ricci, M., & Weinberg, W. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021877 · Cited by 42
Swick, J. M., & Maize, J. C. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.047 · Cited by 42
Caron, J. M., Bannon, M., Rosshirt, L., Luis, J., Monteagudo, L., Caron, J. M., & Sternstein, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011788 · Cited by 42
Autosis: a new addition to the cell death tower of babel
Muñoz‐Pinedo, C., & Martin, S. J. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.246 · Cited by 42
Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence
Shin, J., Yang, J., Lee, J. C., & Baek, K. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.014 · Cited by 41
Conde‐Perez, A., & Larue, L. (2012) · Future Oncology · doi:10.2217/fon.12.106 · Cited by 41
Laine, A., & Westermarck, J. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1942 · Cited by 41
Pan, Y., Meng, M., Zheng, N., Cao, Z., Yang, P., Xi, X., & Zhou, Q. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.024 · Cited by 41
Autocrine IL-6 mediates pituitary tumor senescence
Sapochnik, M., Haedo, M. R., Fuertes, M., Ajler, P. M., Carrizo, G., Cervio, A., Sevlever, G. E., Stalla, G. K., & ARZT, E. S. (2016) · Oncotarget · doi:10.18632/oncotarget.13577 · Cited by 41
McNeal, A. S., Belote, R. L., Zeng, H., Urquijo, M. A., Barker, K., Torres, R., Curtin, M. C., Shain, A. H., Andtbacka, R. H. I., Holmen, S. L., et al. (2021) · eLife · doi:10.7554/elife.70385 · Cited by 41
Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells
Morsli, S., Doherty, G. J., & Muñoz‐Espín, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111618 · Cited by 41
Histiocytose langerhansienne de l’adulte
Néel, A., Artifoni, M., Donadieu, J., Lorillon, G., Hamidou, M. A., & Tazi, A. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.04.015 · Cited by 41
Chung, C., Forte, A. J., Narayan, D., & Persing, J. A. (2006) · Journal of Craniofacial Surgery · doi:10.1097/01.scs.0000231619.95263.a2 · Cited by 41
Pancreatic Cancer Development and Progression: Remodeling the Model
Real, F. X., Cibrián–Uhalte, E., & Martinelli, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.033 · Cited by 41
A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells
Augello, G., Puleio, R., Emma, M. R., Cusimano, A., Loria, G. R., McCubrey, J. A., Montalto, G., & Cervello, M. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1138183 · Cited by 41
Sharpless, N. E., & DePinho, R. A. (2007) · Nature · doi:10.1038/nature05567 · Cited by 41
SnoN functions as a tumour suppressor by inducing premature senescence
Pan, D., Zhu, Q., & Luo, K. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.250 · Cited by 40
Welford, S. M., Dorie, M. J., Li, X., Haase, V. H., & Giaccia, A. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01618-09 · Cited by 40
Eruptive nevi associated with medications (ENAMs)
Perry, B. M., Nguyen, A., Desmond, B., Blattner, C. M., Thomas, R., & Young, R. J. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.064 · Cited by 40
Induction and transmission of oncogene-induced senescence
Rattanavirotkul, N., Kirschner, K., & Chandra, T. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03638-0 · Cited by 41
Vétillard, A., Jonchère, B., Moreau, M., Toutain, B., Henry, C., Fontanel, S., Bernard, A.-C., Campone, M., Guette, C., & Coqueret, O. (2015) · Oncotarget · doi:10.18632/oncotarget.6126 · Cited by 40
Susceptibility of the Aging Lung to Environmental Injury
Wang, L., Green, F., Smiley‐Jewell, S. M., & Pinkerton, K. E. (2010) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0030-1265895 · Cited by 40
Xu, Q., Ma, P., Hu, C., Chen, L., Xue, L., Wang, Z., Liu, M., Zhu, H., Xu, N., & Lü, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041862 · Cited by 40
Hallmarks for senescence in carcinogenesis: novel signaling players
Caino, M. C., Meshki, J., & Kazanietz, M. G. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0316-z · Cited by 40
Marthandan, S., Menzel, U., Priebe, S., Groth, M., Guthke, R., Platzer, M., Hemmerich, P., Kaether, C., & Diekmann, S. (2016) · Biological Research · doi:10.1186/s40659-016-0095-2 · Cited by 39
New Insights on Molecular Mechanisms of Renal Aging
Schmitt, R., & Melk, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04214.x · Cited by 39
Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer
Adjiri, A. (2016) · Oncology and Therapy · doi:10.1007/s40487-015-0015-6 · Cited by 39
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy
Murcia, Ó., Juárez, M., Hernández‐Illán, E., Egoavil, C. M., Giner-Calabuig, M., Soler, M. R., & Jover, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i13.3516 · Cited by 39
Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology
Mancera, N., Smalley, K. S. M., & Margo, C. E. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.12.002 · Cited by 39
The Functional Role of Long Non-Coding RNAs in Melanoma
Woźniak, M., & Czyż, M. (2021) · Cancers · doi:10.3390/cancers13194848 · Cited by 39
Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 39
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 39
Sherman, M. Y., Le, M., Stampfer, M. R., Gabai, V. L., & Yaglom, J. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00736.x · Cited by 39
Controversial aspects of oncogene-induced senescence
Bianchi, A., & Nikiforov, M. A. (2012) · Cell Cycle · doi:10.4161/cc.22589 · Cited by 39
Mouse models for BRAF-induced cancers
Pritchard, C. A., Carragher, L., Aldridge, V., Giblett, S. M., Jin, H., Foster, C., Andreadi, C., & Kamata, T. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351329 · Cited by 39
p35 Is Required for CDK5 Activation in Cellular Senescence
Mao, D., & Hinds, P. W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066118 · Cited by 39
Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Chen, F. W., Tseng, D., Reddy, S. A., DAUD, A. I., & Swetter, S. M. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.838 · Cited by 39
Senescence and serration: a new twist to an old tale
Minoo, P., & Jass, J. R. (2006) · The Journal of Pathology · doi:10.1002/path.2047 · Cited by 39
Maddodi, N., Bhat, K. M. R., Devi, S., Zhang, S., & Setaluri, V. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.068668 · Cited by 39
Advances in melanoma senescence and potential clinical application
Giuliano, S., Ohanna, M., Ballotti, R., & Bertolotto, C. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00820.x · Cited by 39
Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk
Llorca-Cardeñosa, M. J., Peña-Chilet, M., Mayor, M., Gómez‐Fernández, C., Casado, B., Martín‐González, M., Carretero, G., Lluch, A. M., Martínez‐Cadenas, C., Ibarrola‐Villava, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.09.017 · Cited by 39
Current Understanding of the Role of Senescent Melanocytes in Skin Ageing
Hughes, B. K., & Bishop, C. L. (2022) · Biomedicines · doi:10.3390/biomedicines10123111 · Cited by 38
Senescence and pre-malignancy: How do tumors progress?
Saab, R. H. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.013 · Cited by 38
New insights into oncogenic stress
Haigis, K. M., & Sweet-Cordero, A. (2011) · Nature Genetics · doi:10.1038/ng0311-177 · Cited by 38
Connecting cancer relapse with senescence
Pluquet, O., Abbadie, C., & Coqueret, O. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.004 · Cited by 38
Dhomen, N. S., Dias, S. D. R., Hayward, R., Ogilvie, L. M., Hedley, D., Delmas, V., McCarthy, A., Henderson, D. J., Springer, C. J., Pritchard, C. A., et al. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00662.x · Cited by 38
Tanning and Increased Nevus Development in Very-Light-Skinned Children Without Red Hair
Aalborg, J., Morelli, J. G., Mokrohisky, S. T., Asdigian, N. L., Byers, T., Dellavalle, R. P., Box, N. F., & Crane, L. A. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.193 · Cited by 38
Senescence; an endogenous anticancer mechanism
Vargas, J. E. (2012) · Frontiers in bioscience · doi:10.2741/4074 · Cited by 38
BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours
Serrano, C., Simonetti, S., Hernández‐Losa, J., Valverde, C. M., Carrato, C., Bagué, S., Orellana, R., Somoza, R., Moliné, T., Carles, J., et al. (2012) · Histopathology · doi:10.1111/his.12021 · Cited by 38
Lin, Y., Zhen, Y., Wei, J., Liu, B., Zong-yuan, Y., & Hu, G. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.101 · Cited by 38
Rutkowski, P. L., Gos, A., Jurkowska, M., Świtaj, T., Dziewirski, W., Zdzienicki, M., Ptaszyński, K., Michej, W., Tysarowski, A., & SIEDLECKI, J. A. (2014) · Oncology Letters · doi:10.3892/ol.2014.2122 · Cited by 38
Remodeling chromatin for senescence.
Adams, P. D. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00313.x · Cited by 37
Chen, Y.-L., Chen, Y.-J., Tsai, W.-H., Ko, Y.-C., Chen, J.-Y., & Lin, S.-F. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7411 · Cited by 37
L’Hôte, V., Courbeyrette, R., Pinna, G., Cintrat, J., Le Pavec, G., Delaunay‐Moisan, A., Mann, C., & Thuret, J. (2021) · Aging Cell · doi:10.1111/acel.13447 · Cited by 37
Senescence in cancer: Advances in detection and treatment modalities
Billimoria, R., & Bhatt, P. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115739 · Cited by 37
Zhang, X., Zhang, Z., Zou, X., Wang, Y., Qi, J., Han, S. H., Xin, J., Zheng, Z. J., Wei, L., Zhang, T., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1324561 · Cited by 37
Trajectories of premalignancy during the journey from melanocyte to melanoma
Colebatch, A. J., & Scolyer, R. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.09.002 · Cited by 37
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 37
BRAFmutation testing in clinical practice
Ziai, J. M., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.1 · Cited by 37
Landsberg, J., Gaffal, E., Cron, M., Sirokay, J. D., Renn, M., & Tüting, T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00744.x · Cited by 37
Martínez, A. B., LÓPEZ-DURÁN, M., Cano‐Sánchez, J., Sánchez-Verde, L., DÍEZ-RODRÍGUEZ, A., AGUIRRE-ECHEBARRÍA, P., Álvarez‐Fernández, E., González‐Moles, M. Á., Bascones-Ilundáin, J., Muzio, L. L., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.649 · Cited by 37
Tissue engineering of skin and cornea
Paquet, C., Larouche, D., Bisson, F., Proulx, S., Simard‐Bisson, C., Gaudreault, M., Robitaille, H., Carrier, P., Martel, I., Duranceau, L., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05373.x · Cited by 37
Vitali, R., Mancini, C., Cesi, V., Tanno, B., Piscitelli, M., Mancuso, M., Sesti, F., Pasquali, E., Calabretta, B., Dominici, C., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24606 · Cited by 37
A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest
Angus, S. P., & Nevins, J. R. (2012) · Oncogene · doi:10.1038/onc.2011.622 · Cited by 37
The FBXO4 Tumor Suppressor Functions as a Barrier to Braf V600E -Dependent Metastatic Melanoma
Lee, E. K., Lian, Z., D'Andrea, K. P., Letrero, R., Sheng, W., Liu, S., Diehl, J. A., Pytel, D., Barbash, O., Schuchter, L. M., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00706-13 · Cited by 37
Soo, J. K., Ross, A. D. M., Kallenberg, D. M., Milagre, C. S., Chong, W. H., Chow, J. W. M., Hill, L. J., Hoare, S. F., Collinson, R. S., Hossain, M., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00850.x · Cited by 36
DNA damage response in adult stem cells
Insinga, A., Cicalese, A., & Pelicci, P. G. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.12.005 · Cited by 36
Lade‐Keller, J., Riber‐Hansen, R., Guldberg, P., Schmidt, H., Hamilton-Dutoit, S. J., & Steiniche, T. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-202127 · Cited by 36
Flaherty, K. T. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e5357 · Cited by 36
Goedert, L., Plaça, J. R., Fuziwara, C. S., Machado, M. C. R., Plaça, D. R., Almeida, P. P., Sanches, T. P., dos Santos, J. F., Corveloni, A. C., Pereira, I. E. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01957-0 · Cited by 36
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Liu, X., Wu, J., Qin, H., & Xu, J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0565-2 · Cited by 36
Ruiz, R., Chen, C., Razzak, E., Vasudeva, P., Krasieva, T. B., Shiu, J., Caldwell, M. G., Yan, H., Lowengrub, J. S., Ganesan, A. K., et al. (2020) · eLife · doi:10.7554/elife.61026 · Cited by 36
Gualtieri, A., Kyprianou, N., Gregory, L. C., Vignola, M. L., Nicholson, J., Tan, R., Inoue, S., Scagliotti, V., Casado, P., Blackburn, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21712-4 · Cited by 36
Deng, L., He, K., Pan, Y., Wang, H., Luo, Y., & Xia, Q. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.56003 · Cited by 36
Lee, S.-J., Lee, S.-H., Yoon, M.-H., & Park, B.-J. (2013) · Neoplasia · doi:10.1593/neo.121862 · Cited by 36
Replication Stress: A Lifetime of Epigenetic Change
Khurana, S., & Oberdoerffer, P. (2015) · Genes · doi:10.3390/genes6030858 · Cited by 36
At the stem of youth and health
Beltrami, A. P., Cesselli, D., & Beltrami, C. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.005 · Cited by 36
Uncovering the role of hypoxia inducible factor-1α in skin carcinogenesis
Nys, K., Maes, H., Dudek, A. M., & Agostinis, P. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.02.001 · Cited by 36
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 36
New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model
Raabe, E. H., Kieran, M. W., & Cohen, K. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0662 · Cited by 36
Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells
Kong, Y., Kumar, S. M., & Xu, X. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0418-rar.1 · Cited by 36
Haass, N. K., & Smalley, K. S. M. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256334 · Cited by 36
Telomere length of cord blood-derived CD34+ progenitors predicts erythroid proliferative potential
Schuller, C. E., Jankowski, K., & MacKenzie, K. L. (2007) · Leukemia · doi:10.1038/sj.leu.2404631 · Cited by 36
García-Fernández, M., Karras, P., Checinska, A., Cañón, E., Calvo, G. T., Gómez-López, G., Cifdaloz, M., Colmenar, A., Espinosa-Hevia, L., Olmeda, D., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1199301 · Cited by 35
Self-citationThe molecular pathology of cutaneous melanoma
Bogenrieder, T., & Herlyn, M. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0164 · Cited by 35
Progress towards molecular-based management of childhood Langerhans cell histiocytosis
Héritier, S., Emile, J., Hélias‐Rodzewicz, Z., & Donadieu, J. (2019) · Archives de Pédiatrie · doi:10.1016/j.arcped.2019.05.015 · Cited by 35
Metadata
- Authors
- Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Michigan (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Mooi, Wolter J.
- Peeper, Daniel S.
- Venue
- Nature
- Published
- 2005-08
- Volume
- 436
- Issue
- 7051
- Pages
- 720-724
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2150740687
- Semantic Scholar
- bfbf433cb25b4a5e054e35a6850376801a03b87d
- Cited by
- 2,160
- References
- 31
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 70 · 2023: 82 · 2022: 77 · 2021: 85 · 2020: 86 · 2019: 108 · 2018: 99 · 2017: 91 · 2016: 121 · 2015: 112 · 2014: 120 · 2013: 143 · 2012: 136
- FWCI
- 66.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cellular senescence, BRAF V600E mutation, melanocytes, nevi, melanoma, cell cycle arrest, senescence-associated heterochromatin foci, SUV39H1, histone methyltransferase, p16INK4a, p53, PTEN, oncogene-induced senescence, tumor suppression
- MeSH terms
- beta-Galactosidase, Cell Cycle, Cell Line, Fibroblasts, Humans, Infant, Melanocytes, Nevus, Telomere, Cellular Senescence, In Situ Hybridization, Fluorescence, Cyclin-Dependent Kinase Inhibitor p16, Proto-Oncogene Proteins B-raf, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
